Exact Sciences Corporation Net Income per Employee (EXAS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Exact Sciences Corporation  (NASDAQ: EXAS)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Exact Sciences Net Income per Employee

EXAS's Quarterly Results, Trends, Rankings, Statistics
Exact Sciences Corporation recorded a cumulative net loss of $-208 million during 12 month ending in the fourth quarter 2025.
The Healthcare sector has seen employees of 17 other companies achieving higher income per employee. While Exact Sciences's total ranking has deteriorated compared to the previous quarter from 2853 to 3078.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EXAS Net Income per Employee (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -28,882 -137,025 -139,614 -141,645 -142,897
EXAS's Total Ranking # 3078 # 2853 # 2120 # 2876 # 2928
Seq. Net Income Change - - - - -

EXAS Company Profile >> Back to EXAS Efficiency Comparisons >> Compare EXAS Net Income per Employee to its Competitors

EXAS Net Income per Employee Company Ranking
Within: No.
Medical Laboratories Industry # 18
Healthcare Sector # 288
Overall Market # 3078

Net Income per Employee Statistics
High Average Low
$ -6,604 $ -48,308 $ -142,897
(Dec 31 2013)   (Dec 31 2024)




  News about Exact Sciences Corporation Income per employee

Cologuard A Decade of Innovation in Cancer Detection, Saving Lives and Billions in Healthcare Costs

In a landscape where timely cancer detection can mean the difference between life and death, Exact Sciences Corp. has heralded a transformative tool in the diagnostic realm the Cologuard test. The latest modeling data presents a compelling narrative: over the past decade since its FDA approval, this pioneering multi-target stool DNA test has detected more than 623,000 cases of cancer and precancerous lesions, yielding significant benefits for patients and the broader U.S. healthcare system.The Cologuard test stands out not only for its efficacy in identifying early-stage malignancies but also for its role in enhancing patient accessibility to screening options. Designed for those at average risk of colorectal cancer, the test presents a non-invasive alternative to traditional screening methods, thereby mitigating barriers to entry for individuals reluctant or unable to undergo more invasive procedures such as colonoscopy.




Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2025Number of Employees Dec 31 2025


Date modified: 2026-06-22T16:30:41+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.